The most advanced trial to date was the “PRECISE trial,” which infused a fusion toxin that conjugates recombinant human IL-13 with mutant Pseudomonas exotoxin against recurrent glioblastoma.18 This study, however, failed to show statistically significant survival benefits over carmustine wafer implantation. Here, IL13 is linked to glioblastoma.